primary antibodies tfap2a  (Proteintech)

Journal: Biomedical Reports

Article Title: Silencing of lncRNA TFAP2A-AS1 attenuates the development of acute coronary syndrome by inhibiting TFAP2A expression

doi: 10.3892/br.2025.2093

Figure Lengend Snippet: Serum from patients with ACS exhibits elevated expression levels of TFAP2A-AS1 and TFAP2A. The expression of (A) TFAP2A-AS1 and (B) TFAP2A in patients with ACS and healthy individuals was detected by reverse transcription-quantitative PCR. *** P<0.001 vs. Healthy. ACS, acute coronary syndrome; TFAP2A, transcription factor AP-2α.

Article Snippet: Primary antibodies TFAP2A (cat. no. 13019-3-AP), IgG control (cat. no. 30000-0-AP) and GAPDH (cat. no. 60004-1-Ig) were purchased from Proteintech Group, Inc., along with horseradish peroxidase (HRP)-conjugated secondary antibodies (cat. no. SA00001-2).

Techniques: Expressing, Reverse Transcription, Real-time Polymerase Chain Reaction

Journal: Biomedical Reports

Article Title: Silencing of lncRNA TFAP2A-AS1 attenuates the development of acute coronary syndrome by inhibiting TFAP2A expression

doi: 10.3892/br.2025.2093

Figure Lengend Snippet: Silencing of TFAP2A-AS1 suppresses TFAP2A expression. (A) The expression of TFAP2A-AS1 in HCAECs after transfection with TFAP2A-AS1 siRNA1/2/3 or NC siRNA was detected by RT-qPCR. *** P<0.001 vs. NC siRNA. (B) The expression of TFAP2A in HCAECs after transfection with TFAP2A siRNA1/2/3 or NC siRNA was detected by RT-qPCR. *** P<0.001 vs. NC siRNA. (C) The expression of TFAP2A-AS1 and TFAP2A in HCAECs after transfection with TFAP2A-AS1 siRNA, TFAP2A siRNA or NC siRNA was detected by RT-qPCR. *** P<0.001 vs. NC siRNA. (D) The protein levels of TFAP2A in HCAECs after transfection with TFAP2A-AS1 siRNA, TFAP2A siRNA or NC siRNA were determined using western blotting. ** P<0.01 and *** P<0.001 vs. NC siRNA. (E) RIP assay demonstrated an enrichment of TFAP2A-AS1. *** P<0.001 vs. anti-IgG. (F) RNA pull-down assay showed that TFAP2A interacting with biotin-labeled TFAP2A-AS1 was higher than that with the antisense of TFAP2A-AS1 group. TFAP2A, transcription factor AP-2α; HCAECs, human coronary artery endothelial cells; siRNA, small interfering RNA; NC, negative control; RT-qPCR, reverse transcription-quantitative PCR; RIP, RNA immunoprecipitation; ns, no significance.

Article Snippet: Primary antibodies TFAP2A (cat. no. 13019-3-AP), IgG control (cat. no. 30000-0-AP) and GAPDH (cat. no. 60004-1-Ig) were purchased from Proteintech Group, Inc., along with horseradish peroxidase (HRP)-conjugated secondary antibodies (cat. no. SA00001-2).

Techniques: Expressing, Transfection, Quantitative RT-PCR, Western Blot, Pull Down Assay, Labeling, Small Interfering RNA, Negative Control, Reverse Transcription, Real-time Polymerase Chain Reaction, RNA Immunoprecipitation

Journal: Biomedical Reports

Article Title: Silencing of lncRNA TFAP2A-AS1 attenuates the development of acute coronary syndrome by inhibiting TFAP2A expression

doi: 10.3892/br.2025.2093

Figure Lengend Snippet: Silencing of TFAP2A-AS1 and TFAP2A suppresses the proliferative, migratory, and invasive capacities while enhancing the apoptotic rate of HCAECs. (A) The apoptosis rate, (B) viability, (C) invasion and (D) migration of HCAECs transfected TFAP2A-AS1 siRNA, TFAP2A siRNA or NC siRNA was assessed by flow cytometric analysis, Counting Kit-8 assay, Transwell invasion assay and wound healing assay, respectively. Scale bar, 100 µm. *** P<0.001 vs. NC siRNA. TFAP2A, transcription factor AP-2α; HCAECs, human coronary artery endothelial cells; siRNA, small interfering RNA; NC, negative control.

Article Snippet: Primary antibodies TFAP2A (cat. no. 13019-3-AP), IgG control (cat. no. 30000-0-AP) and GAPDH (cat. no. 60004-1-Ig) were purchased from Proteintech Group, Inc., along with horseradish peroxidase (HRP)-conjugated secondary antibodies (cat. no. SA00001-2).

Techniques: Migration, Transfection, Transwell Invasion Assay, Wound Healing Assay, Small Interfering RNA, Negative Control

Journal: Biomedical Reports

Article Title: Silencing of lncRNA TFAP2A-AS1 attenuates the development of acute coronary syndrome by inhibiting TFAP2A expression

doi: 10.3892/br.2025.2093

Figure Lengend Snippet: Knockdown of TFAP2A-AS1 and TFAP2A leads to a reduction in serum lipid levels and an improvement in myocardial injury in an ACS mouse model. (A) The expression of TFAP2A-AS1 and TFAP2A in ACS mice after injection of TFAP2A-AS1 shRNA, TFAP2A shRNA or NC shRNA was detected by reverse transcription-quantitative PCR. (B) The protein levels of TFAP2A in ACS mice after injection of TFAP2A-AS1 shRNA, TFAP2A shRNA or NC shRNA were determined using western blotting. (C) The levels of TC, LDL-C and HDL-C in ACS mice after injection of TFAP2A-AS1 shRNA, TFAP2A shRNA or NC shRNA were determined using biochemical tests. (D) Hematoxylin and eosin staining was performed to observe the pathological condition of myocardial tissues in different groups. Scale bar, 50 µm. *** P<0.001 vs. sham; # P<0.05, ## P<0.01, and ### P<0.001 vs. the ACS model + NC shRNA. TFAP2A, transcription factor AP-2α; ACS, acute coronary syndrome; shRNA, short hairpin RNA; ns, no significance.

Article Snippet: Primary antibodies TFAP2A (cat. no. 13019-3-AP), IgG control (cat. no. 30000-0-AP) and GAPDH (cat. no. 60004-1-Ig) were purchased from Proteintech Group, Inc., along with horseradish peroxidase (HRP)-conjugated secondary antibodies (cat. no. SA00001-2).

Techniques: Knockdown, Expressing, Injection, shRNA, Reverse Transcription, Real-time Polymerase Chain Reaction, Western Blot, Staining